Sanjay Popat

Professor of Thoracic Oncology

Institute of Cancer Research

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Cancer Biology Cancer Biology professors in United Kingdom

Contact this professor

ORCID

Google Scholar

Academic Page

About

Dr. Sanjay Popat is a Professor of Thoracic Oncology at the Institute of Cancer Research in the United Kingdom. His research focuses on the treatment and management of lung cancer, particularly in relation to novel therapies and clinical outcomes. Recent publications include studies on the efficacy of targeted therapies, the impact of diabetes on lung cancer mortality, and the transportability of real-world evidence for health technology assessment.

Sanjay Popat

Research Interests

Explore related searches

Contact this professor

About

Articles (24)

Data set for the reporting of lung cancer: recommendations from the International Collaboration on Cancer Reporting (ICCR)

Durable Response to Lenvatinib in Platinum-Refractory Metastatic High-Grade Thymic Mucoepidermoid Carcinoma: A Case Report

Transportability of nonlocal real-world evidence and its relevance to health technology assessment: a primer

Mortality Outcomes in People with Lung Cancer with and without Type2 Diabetes: A Cohort Study in England

A randomised phase III study of bevacizumab and carboplatin–pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial

Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials

Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy

FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)

Immunotherapy in EGFR-Mutant Non–Small Cell Lung Cancer: End of the Road or the First Chapter?

Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H family

Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers

Inoperable stage III EGFR mutant non-small-cell lung cancer: time for drug first, local later?

RETaliation—Tackling Rare Resistance Alterations to Osimertinib

A Subset of Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Show 18F-Fluorothymidine “Flare” on Positron Emission Tomography

Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

Amivantamab Compared with Real-World Physician’s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations

Adjuvant immune checkpoint inhibitor therapy for resected non-small-cell lung cancer: dessert, starters, or a sandwich?

Response to letter entitled: Re: ‘Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib'

Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase–positive non–small cell lung cancer using data from ALEX and final results from ALTA-1L

Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes

Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla™ EGFR mutation test but is detected by ctDNA next generation sequencing and responds to osimertinib

Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)

Collaborators (8)

Benjamin Besse

Matthew Krebs

Joachim G. Aerts

Yasushi YATABE

Pilar Garrido López

Eric O. Aboagye

Anthonie van der Wekken

Jennifer Quint

How do I reach out?

Meet Kite AI